American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J.

Risultato della ricerca: Article

Abstract

Objective: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRI cSLE ). Methods: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRI cSLE and rate a total of 433 unique patient profiles for the presence/absence of CRI cSLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE-CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0–1). Results: During an international consensus conference, unanimous agreement on a definition of CRI cSLE was achieved; cSLE experts (n = 13) concurred (100%) that the preferred CHILI algorithm considers absolute changes in the cSLE-CRVs. After transformation to a range of 0–100, a CHILI score of ≥54 had outstanding accuracy for identifying CRI cSLE (AUC 0.93, sensitivity 81.1%, and specificity 84.2%). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC ≥0.92, sensitivity ≥93.1%, and specificity ≥73.4%). Conclusion: The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.
Lingua originaleEnglish
pagine (da-a)579-590
Numero di pagine12
RivistaARTHRITIS CARE & RESEARCH
Volume71
Stato di pubblicazionePublished - 2019

Cita questo

Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J. (2019). American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. ARTHRITIS CARE & RESEARCH, 71, 579-590.

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. / Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J.

In: ARTHRITIS CARE & RESEARCH, Vol. 71, 2019, pag. 579-590.

Risultato della ricerca: Article

Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J. 2019, 'American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus' ARTHRITIS CARE & RESEARCH, vol. 71, pagg. 579-590.
Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. ARTHRITIS CARE & RESEARCH. 2019;71:579-590.
Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J. / American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. In: ARTHRITIS CARE & RESEARCH. 2019 ; Vol. 71. pagg. 579-590.
@article{58dfe6dacf844c759da3a3a44d0715f1,
title = "American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus",
abstract = "Objective: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRI cSLE ). Methods: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRI cSLE and rate a total of 433 unique patient profiles for the presence/absence of CRI cSLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE-CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0–1). Results: During an international consensus conference, unanimous agreement on a definition of CRI cSLE was achieved; cSLE experts (n = 13) concurred (100{\%}) that the preferred CHILI algorithm considers absolute changes in the cSLE-CRVs. After transformation to a range of 0–100, a CHILI score of ≥54 had outstanding accuracy for identifying CRI cSLE (AUC 0.93, sensitivity 81.1{\%}, and specificity 84.2{\%}). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC ≥0.92, sensitivity ≥93.1{\%}, and specificity ≥73.4{\%}). Conclusion: The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.",
author = "{Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Feldman, B.; Ying, J.; Battagliotti, C.; Brusco, M.; Cuttica, R.; De Cunto, C.; Espada, G.; Farfan, M.; Garay, S.; Marcantoni, M.; Marcela, A.; Meiorin, S.; Rama, M.; Russo, R.; Torre Walsh, C.; Zamparo, C.; Adib, N.; Akikusa, J.} and Maggio, {Maria Cristina}",
year = "2019",
language = "English",
volume = "71",
pages = "579--590",
journal = "ARTHRITIS CARE & RESEARCH",
issn = "2151-464X",

}

TY - JOUR

T1 - American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

AU - Brunner, H.; Holland, M.; Beresford, M.; Ardoin, S.; Appenzeller, S.; Silva, C.; Flores, F.; Goilav, B.; Avar Aydin, P.; Wenderfer, S.; Levy, D.; Ravelli, A.; Khubchandani, R.; Avcin, T.; Klein-Gitelman, M.; Ruperto, N.; Fe

AU - Maggio, Maria Cristina

PY - 2019

Y1 - 2019

N2 - Objective: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRI cSLE ). Methods: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRI cSLE and rate a total of 433 unique patient profiles for the presence/absence of CRI cSLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE-CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0–1). Results: During an international consensus conference, unanimous agreement on a definition of CRI cSLE was achieved; cSLE experts (n = 13) concurred (100%) that the preferred CHILI algorithm considers absolute changes in the cSLE-CRVs. After transformation to a range of 0–100, a CHILI score of ≥54 had outstanding accuracy for identifying CRI cSLE (AUC 0.93, sensitivity 81.1%, and specificity 84.2%). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC ≥0.92, sensitivity ≥93.1%, and specificity ≥73.4%). Conclusion: The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.

AB - Objective: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRI cSLE ). Methods: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRI cSLE and rate a total of 433 unique patient profiles for the presence/absence of CRI cSLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Erythematosus Disease Activity Index), urine protein-to-creatinine ratio, and Child Health Questionnaire physical summary score. Percentage and absolute changes in these cSLE-CRVs (baseline versus follow-up) were considered in order to develop candidate algorithms and validate their performance (sensitivity, specificity, area under the receiver operating characteristic curve [AUC]; range 0–1). Results: During an international consensus conference, unanimous agreement on a definition of CRI cSLE was achieved; cSLE experts (n = 13) concurred (100%) that the preferred CHILI algorithm considers absolute changes in the cSLE-CRVs. After transformation to a range of 0–100, a CHILI score of ≥54 had outstanding accuracy for identifying CRI cSLE (AUC 0.93, sensitivity 81.1%, and specificity 84.2%). CHILI scores also reflect minor, moderate, and major improvement for values exceeding 15, 68, and 92, respectively (all AUC ≥0.92, sensitivity ≥93.1%, and specificity ≥73.4%). Conclusion: The CHILI is a new, seemingly highly accurate index for measuring CRI in cSLE over time. This index is useful to categorize the degree of response to therapy in children and adolescents with cSLE.

UR - http://hdl.handle.net/10447/356484

UR - http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658

M3 - Article

VL - 71

SP - 579

EP - 590

JO - ARTHRITIS CARE & RESEARCH

JF - ARTHRITIS CARE & RESEARCH

SN - 2151-464X

ER -